Trial Profile
A randomised double blind placebo controlled clinical trial of anti-B-cell therapy in patients with primary Sjogrens syndrome
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Dec 2023
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Sjogren's syndrome
- Focus Therapeutic Use
- Acronyms TRACTISS
- 10 Dec 2023 Results assessing to identify peripheral and salivary gland (SG) biomarkers of response/resistance to B-cell depletion based on the novel concise CRESS and candidate STAR composite endpoints in TRACTISS trial of Sjogren's syndrome, published in the Arthritis and Rheumatology.
- 04 Jun 2022 Results (n=29)of first longitudinal analysis of matched transcriptomic and histological data of SG biopsies of pSS patients treated with RTX vs placebo at 3 time points, over 48 weeks, presented at the 23rd Annual Congress of the European League Against Rheumatism
- 09 Nov 2021 Results from two RCTs ASAP-III and TRACTISS trials in Patients with Primary Sjogren's Syndrome presented at the ACR Convergence 2021